Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476657 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by SecuraBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT01476657: Clinical Trial Phase 1 study, sponsored by SecuraBio.
NCT01476657 is a Phase 1 study that was terminated before completion, run by SecuraBio. The registered enrollment target is 210 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476657, a Phase 1 study, was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
Primary Outcome
To determine the incidence of adverse events and abnormal laboratory test results, including dose-limiting toxicities.
Interventions
- DRUG IPI-145 (duvelisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Why NCT01476657 stopped before completion
NCT01476657 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher).
The record links to 0 conditions, and to 1 intervention - of which IPI-145 (duvelisib) is the first listed.
NCT01476657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01476657 about?
NCT01476657 is a clinical study titled "A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies". The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
What is the current status of trial NCT01476657?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2011-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01476657?
The interventions under investigation include: IPI-145 (duvelisib) (DRUG).
Who is sponsoring clinical trial NCT01476657?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01476657's enrollment target sits among peer trials
210 245th of 2000 higher than 1,751 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia